|Crizotinib||Oncology||ALK||ALK gene |
|Indications and Usage, Dosage and Administration, Adverse Reactions,|
* Therapeutic areas do not necessarily reflect the CDER review division.
† Standard nomenclature is used for genes as per the Human Genome Organization symbol, cytogenetic abnormalities as per the International System for Human Cytogenetic Nomenclature, or other conventions.
back to Pharmacogenomic Biomarkers in Drug Labeling